Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs

Key Takeaways

• IRA's Medicare price negotiations become de facto reference points for payers
• Payers shift to friction‑based utilization management, tightening specialty drug formularies
• OBBBA reforms drive coverage churn, increasing forecasting volatility for manufacturers
• MFN pricing pulls U.S. specialty drug prices toward global benchmarks
• Manufacturers must integrate global and domestic strategies early to mitigate risk

Pulse Analysis

The Inflation Reduction Act has moved from a legislative blueprint to an operational force, with Medicare’s first negotiated prices slated for January 2026. These benchmarks are no longer symbolic; they are now embedded in payer contracts and PBM negotiations, establishing a de facto floor that compresses pricing levers across the board. As a result, manufacturers face reduced flexibility in setting launch prices, especially for oncology and immunology therapies that command premium pricing.

Concurrently, the One Big, Beautiful Bill Act and renewed Most Favored Nation provisions are intensifying coverage churn and expanding the use of international reference pricing. Payers, wary of escalating financial risk, are deploying friction‑based utilization management—prior authorizations, step edits, and tighter formularies—to curb spending on high‑cost specialty drugs. This heightened scrutiny accelerates the cycle of patient enrollment and disenrollment, eroding adherence and complicating revenue forecasts for biotech firms.

In this volatile environment, manufacturers must adopt a proactive, integrated strategy that aligns global launch sequencing with domestic pricing realities. Early modeling of MFN tail risk, revisiting value frameworks, and synchronizing cross‑border pricing tactics can mitigate the narrowing pricing corridor. Companies that embed policy monitoring into daily decision‑making will be better positioned to navigate the shifting landscape, preserve market access, and protect asset value amid relentless regulatory pressure.